US-based Epic Sciences, a biotech and cancer diagnostics company, has raised $13m in Series B financing. The capital includes new investors Domain Associates, Roche Venture Fund, the corporate venturing unit of the Switzerland-based pharmaceutical company, and Pfizer Venture Investments, the corporate venturing unit of the US-based healthcare company. At the same time Kim Kamdar, a partner at Domain Associates, has joined its board.
The Californian company focuses on identifying and characterising rare cancers such as circulating tumour cells.
Kamdar said: “Epic’s technology has achieved an unprecedented level of sensitivity un detecting circulating tumour cells to develop crucial cancer diagnostics for the millions of patients who need to understand whether their treatment is working and the status of their disease.”
Kamdar added: “With deep vertical integration of expertise in engineering, computation, pathology and oncology, we see that Epic’s technology will not only have a major impact on clinical cancer treatments but also on the development of new cancer therapeutics and companion diagnostics.”